BMY's Sotyktu FDA Approval: Incremental Positive Amid Core Thesis Unchanged

What happened

The U.S. FDA has approved Bristol Myers Squibb's Sotyktu for psoriatic arthritis, expanding its indications in the immunology market. Sotyktu is part of BMY's Growth Portfolio, which grew 17% in FY2025 but saw only a 4% increase for Sotyktu in Q4'25, indicating modest prior traction. This approval could enhance Sotyktu's sales by accessing a new patient population, but it does not address BMY's larger near-term challenges. Key among these are Eliquis facing IRA-driven price resets and Revlimid erosion accelerating after January 2026, with the investment thesis hinging on gross margin stability. Thus, while the approval is a positive step, it remains a minor factor in the broader portfolio transition narrative.

Implication

The FDA approval for Sotyktu in psoriatic arthritis may modestly boost BMY's growth portfolio by expanding its market reach. However, Sotyktu's historical growth has been tepid, suggesting commercial execution could limit its impact. Investors should monitor post-approval sales data to assess if it meaningfully contributes to offsetting legacy erosion. Crucially, this development does not mitigate the policy-fragile economics of Eliquis or the imminent Revlimid cliff, which are central to the investment case. Therefore, the focus remains on upcoming quarterly results for confirmation of guided Eliquis growth and gross margin stability.

Thesis delta

The Sotyktu FDA approval slightly strengthens the growth portfolio narrative but does not shift the core investment thesis. The thesis still depends on Eliquis delivering +10-15% growth with gross margins holding at 69-70%, and this news does not alter the key risks or the need for observable proof points. No material change to the 'WAIT' rating is justified, as the approval is incremental amidst larger uncertainties.